Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

DLTs = dose-limiting toxicities

MTD = Maximum tolerated dose

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is
considered appropriate

- Subjects with non-small cell lung cancer and triple-negative breast cancer are
preferred

- Biopsy accessible tumor (may use archived tumor samples under certain circumstances)

- Life expectancy of at least 3 months

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

- Measurable disease

Exclusion Criteria:

- Uncontrolled brain metastases

- Infection

- Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory bowel
disease)

- Uncontrolled or significant cardiovascular disease

- Subjects taking medications known to increase risk of Torsades de Pointes